| Diabetes Treatment and Management | Lifetime | 102 | DE 3 | 99.51 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 105 | DE 5 | 98.91 |
| Metabolism, Diabetes, and Cancer | Lifetime | 231 | DE 13 | 98.99 |
| Cardiovascular Function and Risk Factors | Lifetime | 591 | DE 29 | 98.96 |
| Diabetes Management and Research | Lifetime | 376 | DE 17 | 98.63 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 347 | DE 27 | 98.40 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 252 | DE 12 | 98.11 |
| Heart Failure Treatment and Management | Lifetime | 806 | DE 47 | 97.26 |
| Lipoproteins and Cardiovascular Health | Lifetime | 804 | DE 27 | 96.92 |
| Pharmacology and Obesity Treatment | Lifetime | 425 | DE 21 | 95.58 |
| NF-κB Signaling Pathways | Lifetime | 746 | DE 71 | 93.99 |
| Potassium and Related Disorders | Lifetime | 568 | DE 22 | 90.32 |
| Diabetes Treatment and Management | 2021-2025 | 42 | DE 3 | 99.59 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 22 | DE 2 | 99.30 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 202 | DE 15 | 98.47 |
| Diabetes Management and Research | 2021-2025 | 177 | DE 9 | 97.48 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 124 | DE 7 | 96.62 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 161 | DE 7 | 95.39 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 162 | DE 6 | 96.39 |
| Heart Failure Treatment and Management | 2021-2025 | 303 | DE 20 | 96.25 |
| Pancreatic function and diabetes | 2021-2025 | 279 | DE 14 | 95.14 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 709 | DE 38 | 95.60 |
| Potassium and Related Disorders | 2021-2025 | 89 | DE 4 | 92.39 |
| Dialysis and Renal Disease Management | 2021-2025 | 485 | DE 11 | 92.03 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 759 | DE 40 | 85.44 |
| Pharmacology and Obesity Treatment | 2021-2025 | 216 | DE 11 | 84.26 |
| Clinical practice guidelines implementation | 2021-2025 | 385 | DE 33 | 79.69 |
| Parathyroid Disorders and Treatments | 2021-2025 | 793 | DE 34 | 81.05 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 332 | DE 18 | 78.54 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 826 | DE 44 | 76.84 |
| Hormonal Regulation and Hypertension | 2021-2025 | 998 | DE 66 | 78.06 |
| Caveolin-1 and cellular processes | 2021-2025 | 262 | DE 8 | 50.18 |
| Dermatological and Skeletal Disorders | 2021-2025 | 988 | DE 78 | 31.05 |
